- Home
- TLSI vs HRZN Comparison
TLSI vs HRZN Comparison
Compare TLSI & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLSI | HRZN |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.3M | 295.1M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | TLSI | HRZN |
|---|---|---|
| Price | $5.43 | $6.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.50 | $7.13 |
| AVG Volume (30 Days) | 118.9K | ★ 843.7K |
| Earning Date | 11-13-2025 | 03-03-2026 |
| Dividend Yield | N/A | ★ 19.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $40,207,000.00 | ★ $98,899,000.00 |
| Revenue This Year | $55.47 | $3.03 |
| Revenue Next Year | $40.05 | $10.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 49.52 | N/A |
| 52 Week Low | $3.42 | $5.71 |
| 52 Week High | $7.95 | $9.99 |
Technical Indicators
Market Signals| Indicator | TLSI | HRZN |
|---|---|---|
| Relative Strength Index (RSI) | 38.68 | 54.22 |
| Support Level | $5.24 | $6.54 |
| Resistance Level | $5.87 | $6.73 |
| Average True Range (ATR) | 0.41 | 0.11 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 18.35 | 60.34 |
Price Performance
Historical ComparisonAbout TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.